ATE144897T1 - Zusammensetzung, die rhodacyanine-farbstoffen enthält, zur behandlung von krebs - Google Patents

Zusammensetzung, die rhodacyanine-farbstoffen enthält, zur behandlung von krebs

Info

Publication number
ATE144897T1
ATE144897T1 AT92113812T AT92113812T ATE144897T1 AT E144897 T1 ATE144897 T1 AT E144897T1 AT 92113812 T AT92113812 T AT 92113812T AT 92113812 T AT92113812 T AT 92113812T AT E144897 T1 ATE144897 T1 AT E144897T1
Authority
AT
Austria
Prior art keywords
different
same
group
chem
alkyl group
Prior art date
Application number
AT92113812T
Other languages
English (en)
Inventor
Tadao Shishido
Original Assignee
Fuji Photo Film Co Ltd
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuji Photo Film Co Ltd, Dana Farber Cancer Inst Inc filed Critical Fuji Photo Film Co Ltd
Application granted granted Critical
Publication of ATE144897T1 publication Critical patent/ATE144897T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Luminescent Compositions (AREA)
  • Gas Separation By Absorption (AREA)
  • Paper (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT92113812T 1991-08-13 1992-08-13 Zusammensetzung, die rhodacyanine-farbstoffen enthält, zur behandlung von krebs ATE144897T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74413091A 1991-08-13 1991-08-13

Publications (1)

Publication Number Publication Date
ATE144897T1 true ATE144897T1 (de) 1996-11-15

Family

ID=24991548

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92113812T ATE144897T1 (de) 1991-08-13 1992-08-13 Zusammensetzung, die rhodacyanine-farbstoffen enthält, zur behandlung von krebs

Country Status (15)

Country Link
US (1) US5360803A (de)
EP (1) EP0527494B1 (de)
JP (1) JP2567328B2 (de)
CN (1) CN1071834A (de)
AT (1) ATE144897T1 (de)
AU (1) AU649865B2 (de)
CA (1) CA2075750C (de)
DE (1) DE69215035T2 (de)
DK (1) DK0527494T3 (de)
ES (1) ES2096685T3 (de)
FI (1) FI923604A (de)
GR (1) GR3021865T3 (de)
HU (1) HUT64224A (de)
NO (1) NO923126L (de)
ZA (1) ZA926004B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599825A (en) * 1994-07-21 1997-02-04 Fuji Photo Film Co., Ltd. Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same
CA2187445A1 (en) * 1994-07-21 1996-02-08 Noriaki Tatsuta Water-soluble methine compound and pharmaceutical composition for treatment of cancer comprising the same
JPH0921985A (ja) * 1995-07-07 1997-01-21 Nec Corp マッハツェンダー変調器及びその製造方法
EP0761216B1 (de) 1995-08-16 2003-11-12 Huntington Medical Research Institutes Rhodamin 123 Zusammensetzungen für Behandlung von Prostatakrebs
US7329741B2 (en) * 1996-06-05 2008-02-12 Chiron Corporation Polynucleotides that hybridize to DP-75 and their use
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10032290C2 (de) * 2000-07-03 2002-05-08 Roche Diagnostics Gmbh Adsorptionsmittelhaltige Kontrollflüssigkeit
JP2003034641A (ja) * 2001-07-19 2003-02-07 Japan Science & Technology Corp ロダシアニン系色素化合物を含有する抗マラリア剤
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
JP2004331545A (ja) * 2003-05-06 2004-11-25 Japan Science & Technology Agency 抗リーシュマニア剤
FR2874319B1 (fr) * 2004-08-19 2008-05-16 Oreal Composition pour la teinture des fibres keratiniques comprenant un colorant direct methinique contenant un motif benzoselenazolium
JP4553355B2 (ja) 2004-10-04 2010-09-29 富士フイルム株式会社 トリパノソーマ原虫寄生感染症の予防又は治療用医薬組成物
US20060099712A1 (en) * 2004-11-08 2006-05-11 Eastman Kodak Company Correlation of anti-cancer activity of dyes with redox potentials
US8293716B2 (en) 2005-05-26 2012-10-23 Ramot At Tel Aviv University Ltd. Method of treating cancer by modulation of mortalin
GB0603455D0 (en) * 2006-02-21 2006-04-05 Cancer Rec Tech Ltd Therapeutic compounds
US20110059070A1 (en) * 2006-09-14 2011-03-10 Ramot At Tel Aviv University Ltd. Combination therapy for tumoral desease treatment
WO2009040819A2 (en) 2007-09-25 2009-04-02 Ramot At Tel Aviv University Ltd. DOWN-REGULATION OF MORTALIN BY siRNA
US9642843B2 (en) 2013-02-27 2017-05-09 The Regents Of The University Of Michigan Pharmaceutical compounds and use of same in cancer and tauopathies
CN104177312B (zh) * 2013-05-27 2018-02-13 黄英武 一种含硒化合物及其医药用途
US10221171B2 (en) 2015-01-09 2019-03-05 The Regents Of The University Of California Oxathiazole thiazolium Hsp 70 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2536986A (en) * 1951-01-02 Thiazolone cyan
GB487051A (en) * 1936-11-14 1938-06-14 John David Kendall Improvements in or relating to dyestuffs
GB489335A (en) * 1937-01-22 1938-07-22 Douglas James Fry Improvements in or relating to the manufacture and use of dyestuffs suitable for sensitising photographic emulsions
US2454629A (en) * 1940-01-27 1948-11-23 Eastman Kodak Co Polymethine dyes
BE485785A (de) * 1947-11-18
BE571507A (de) * 1957-09-30
DE1493524A1 (de) * 1962-08-17 1969-06-04 Ciba Geigy Aminosaeuren
JPS53144727A (en) * 1977-05-24 1978-12-16 Konishiroku Photo Ind Co Ltd Photographic product
DE2919447A1 (de) * 1978-05-17 1979-11-22 Takeda Chemical Industries Ltd Tumorhemmendes mittel
JPS5569513A (en) * 1978-11-20 1980-05-26 Takeda Chem Ind Ltd Anti-tumor agent
JPS55100318A (en) * 1979-01-26 1980-07-31 Takeda Chem Ind Ltd Antitumorigenic agent
JPS54151133A (en) * 1978-05-17 1979-11-28 Takeda Chem Ind Ltd Antitumorigenic agent
AU1144688A (en) * 1987-03-17 1988-09-15 Dana-Farber Cancer Institute, Inc. A pharmaceutical composition comprising cyanine dye
JPH0652210B2 (ja) * 1987-08-26 1994-07-06 宣行 杉村 アキユムレ−タのガス封入圧力測定方法
JP2824917B2 (ja) * 1989-08-30 1998-11-18 株式会社林原生物化学研究所 抗腫瘍剤

Also Published As

Publication number Publication date
FI923604A (fi) 1993-02-14
AU2097492A (en) 1993-02-25
EP0527494B1 (de) 1996-11-06
CA2075750C (en) 1998-02-24
DE69215035D1 (de) 1996-12-12
JPH06172330A (ja) 1994-06-21
ES2096685T3 (es) 1997-03-16
NO923126L (no) 1993-02-15
HU9202609D0 (en) 1992-10-28
CN1071834A (zh) 1993-05-12
US5360803A (en) 1994-11-01
EP0527494A1 (de) 1993-02-17
JP2567328B2 (ja) 1996-12-25
NO923126D0 (no) 1992-08-11
DK0527494T3 (da) 1996-11-25
GR3021865T3 (en) 1997-03-31
AU649865B2 (en) 1994-06-02
DE69215035T2 (de) 1997-04-03
ZA926004B (en) 1993-03-02
HUT64224A (en) 1993-12-28
CA2075750A1 (en) 1993-02-14
FI923604A0 (fi) 1992-08-12

Similar Documents

Publication Publication Date Title
ATE144897T1 (de) Zusammensetzung, die rhodacyanine-farbstoffen enthält, zur behandlung von krebs
DE69232336T2 (de) Stickstoff enthaltende hydrocyclische verbindungen
IE802612L (en) Bicyclo £2.2.1| heptane derivatives
HU9603433D0 (en) Novel 4-6-diaryl-pyrimidine-derivatives and salts thereof
ATE224T1 (de) 1,2-dihydro-chinolin-2-on-derivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel.
NO306992B1 (no) Quinolinderivater, farmasoeytiske preparater inneholdende forbindelsene og anvendelsen av forbindelsene
JO1617B1 (en) Modern 2-amino-tetraline-8 compounds
ATE32894T1 (de) Thiomethylpyridin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
GB1223501A (en) Novel halogenated salicylaldehyde schiff's bases
DE3267188D1 (en) Hydroxybenzylamino-aryl compounds, process for preparing and pharmaceutical compositions containing the same
DE69201848T2 (de) Verfahren zum Härten von Gelatine.
FR2398499A1 (fr) Nouvelles compositions pharmaceutiques a base de derives de l'imidazole pour inhiber la secretion de la prolactine
TH17758A (th) สารเคมี
ATE44741T1 (de) 2-(n-substituierte guanidino)-4heteroarylthiazole als mittel gegen geschwuere.
TH8849EX (th) 8-ซับสทิทิวเทด-2-อะมิโนเททระลีนชนิดใหม่
TH5413A (th) อนุพันธ์โครแมนชนิดใหม่
BE900322A (fr) Nouveaux derives du 1,2,4-triazole.